Physician profile
Wu Tan
NPI 1518236181
$19,318.87
in general payments reported to CMS, 2019-2025
41 companies · $4,613 in 2025
The $4,613 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $369 · 2021: $1,452 · 2022: $2,951 · 2023: $4,194 · 2024: $5,417 · 2025: $4,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,986.10 |
| Education | $237.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $1,654.89 | 2021-2025 | Nexletol |
| Abbvie INC. | $1,648.75 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,589.89 | 2019-2025 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $1,418.88 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,166.19 | 2021-2025 | Farxiga, Breztri, Lokelma |
| Pfizer INC. | $1,060.45 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $872.62 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Genzyme Corporation | $829.82 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $827.97 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $805.86 | 2021-2025 | Rybelsus, Ozempic |
| Teva Pharmaceuticals USA, INC. | $777.56 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Bayer Healthcare Pharmaceuticals INC. | $718.08 | 2021-2025 | |
| Glaxosmithkline, LLC. | $624.64 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $577.94 | 2020-2024 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $528.32 | 2022-2025 | Evenity, Prolia, Repatha |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wu Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.